Kochupurackal P Mohanakumar

List of Publications by Year
in descending order

110 papers	4,178 citations	101543 36 h-index	128289 60 g-index
110 all docs	110 docs citations	110 times ranked	4395 citing authors

#	Article	IF	Citations
1	Neuro-nutraceuticals: Natural products nourish the brain but be aware of contrary effects. Neurochemistry International, 2021, 150, 105159.	3.8	5
2	The light at the end of the tunnel gets vivid for spinal muscular atrophy. Journal of Neurochemistry, 2020, 153, 545-548.	3.9	2
3	Neural functions of the aging brain: Daily living, developmental and geriatric disabilities. Journal of Chemical Neuroanatomy, 2019, 95, 1-5.	2.1	1
4	Nimodipine attenuates the parkinsonian neurotoxin, MPTP-induced changes in the calcium binding proteins, calpain and calbindin. Journal of Chemical Neuroanatomy, 2019, 95, 89-94.	2.1	18
5	Reinforcing mitochondrial functions in aging brain: An insight into Parkinson's disease therapeutics. Journal of Chemical Neuroanatomy, 2019, 95, 29-42.	2.1	25
6	Gender-Specific Effect of 5-HT and 5-HIAA on Threshold Level of Behavioral Symptoms and Sex-Bias in Prevalence of Autism Spectrum Disorder. Frontiers in Neuroscience, 2019, 13, 1375.	2.8	13
7	Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinsonâ€™s Disease. Molecular Neurobiology, 2018, 55, 804-821.	4.0	47
8	Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinsonâ€™s Disease?. Molecular Neurobiology, 2018, 55, 822-834.	4.0	28
9	Pilot study indicate role of preferentially transmitted monoamine oxidase gene variants in behavioral problems of male ADHD probands. BMC Medical Genetics, 2017, 18, 109.	2.1	11
10	Aging and Neurodegeneration: A Tangle of Models and Mechanisms. , 2016, 7, 111.		44
11	Monoamine oxidase B gene variants associated with attention deficit hyperactivity disorder in the Indo-Caucasoid population from West Bengal. BMC Genetics, 2016, 17, 92.	2.7	7
12	Genetic variants of MAOB affect serotonin level and specific behavioral attributes to increase autism spectrum disorder (ASD) susceptibility in males. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 71, 123-136.	4.8	20
13	Attention deficit-hyperactivity disorder suffers from mitochondrial dysfunction. BBA Clinical, 2016, 6, 153-158.	4.1	38
14	Neuro-nutraceuticals: Further insights into their promise for brain health. Neurochemistry International, 2016, 95, 1-3.	3.8	21
15	Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Neurochemistry International, 2016, 99, 221-232.	3.8	44
16	Quercetin improves the activity of the ubiquitinâ€proteasomal system in 150Q mutated huntingtinâ€expressing cells but exerts detrimental effects on neuronal survivability. Journal of Neuroscience Research, 2015, 93, 1581-1591.	2.9	18
17	Serotonin mediated immunoregulation and neural functions: Complicity in the aetiology of autism spectrum disorders. Neuroscience and Biobehavioral Reviews, 2015, 55, 413-431.	6.1	23
18	Melatonin enhances <scp>L</scp>â€<scp>DOPA</scp> therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridineâ€induced parkinsonism in mice. Journal of Pineal Research, 2015, 58, 262-274.	7.4	60

#	Article	IF	Citations
19	Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease. Free Radical Research, 2015, 49, 1129-1139.	3.3	17
20	Neuro-nutraceuticals: The path to brain health via nourishment is not so distant. Neurochemistry International, 2015, 89, 1-6.	3.8	38
21	Embryonic Stem Cells Derived Neuron Transplantation Recovery in Models of Parkinsonism in Relation to Severity of the Disorder in Rats. Rejuvenation Research, 2015, 18, 173-184.	1.8	4
22	Tea and Parkinson's disease: Constituents of tea synergize with antiparkinsonian drugs to provide better therapeutic benefits. Neurochemistry International, 2015, 89, 181-190.	3.8	32
23	SLC6A4 markers modulate platelet 5-HT level and specific behaviors of autism: A study from an Indian population. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 196-206.	4.8	30
24	Mitochondrial Deficits Accompany Cognitive Decline Following Single Bilateral Intracerebroventricular Streptozotocin. Current Alzheimer Research, 2015, 12, 785-795.	1.4	31
25	Profilin-2 increased expression and its altered interaction with Î²-actin in the striatum of 3-nitropropionic acid-induced Huntingtonâ€™s disease in rats. Neuroscience, 2014, 281, 216-228.	2.3	11
26	Quercetin Improves Behavioral Deficiencies, Restores Astrocytes and Microglia, and Reduces Serotonin Metabolism in 3â€Nitropropionic Acidâ€Induced Rat Model of Huntington's Disease. CNS Neuroscience and Therapeutics, 2014, 20, 10-19.	3.9	101
27	Regenerative Therapy in Experimental Parkinsonism: Mixed Population of Differentiated Mouse Embryonic Stem Cells, Rather Than Magnetically Sorted and Enriched Dopaminergic Cells Provide Neuroprotection. CNS Neuroscience and Therapeutics, 2014, 20, 717-727.	3.9	6
28	Sexual dimorphic effect in the genetic association of monoamine oxidase A (MAOA) markers with autism spectrum disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 11-20.	4.8	39
29	Potential Contribution of Monoamine Oxidase A Gene Variants in ADHD and Behavioral Co-Morbidities: Scenario in Eastern Indian Probands. Neurochemical Research, 2014, 39, 843-852.	3.3	12
30	Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease. Behavioural Brain Research, 2014, 264, 91-104.	2.2	38
31	A mitochondrial basis for Huntingtonâ€™s disease: therapeutic prospects. Molecular and Cellular Biochemistry, 2014, 389, 277-291.	3.1	14
32	The Legacy of Nitric Oxide: Impact on Disease Biology. Nitric Oxide - Biology and Chemistry, 2014, 43, 1-2.	2.7	3
33	Melatonin synergizes with low doses of Lâ€<scp>DOPA</scp> to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. Journal of Pineal Research, 2013, 55, 304-312.	7.4	42
34	Neuroprotective Potential of Silymarin against <scp>CNS</scp> Disorders: Insight into the Pathways and Molecular Mechanisms of Action. CNS Neuroscience and Therapeutics, 2013, 19, 847-853.	3.9	79
35	Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinsonâ€™s disease in rats. Neuroscience, 2013, 236, 136-148.	2.3	179
36	Nitric oxide synthase inhibitors protect against rotenone-induced, oxidative stress mediated parkinsonism in rats. Neurochemistry International, 2013, 62, 674-683.	3.8	28

#	Article	IF	Citations
37	Parkinson's disease cybrids, differentiated or undifferentiated, maintain morphological and biochemical phenotypes different from those of control cybrids. Journal of Neuroscience Research, 2013, 91, 963-970.	2.9	13
38	Sodium salicylate protects against rotenone-induced Parkinsonism in rats. Synapse, 2013, 67, 502-514.	1.2	26
39	Engraftment of Mouse Embryonic Stem Cells Differentiated by Default Leads to Neuroprotection, Behaviour Revival and Astrogliosis in Parkinsonian Rats. PLoS ONE, 2013, 8, e72501.	2.5	12
40	L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinsonâ€™s disease patients. Medical Hypotheses, 2012, 79, 271-273.	1.5	31
41	Antiparkinsonian Effects of Aqueous Methanolic Extract of Hyoscyamus niger Seeds Result From its Monoamine Oxidase Inhibitory and Hydroxyl Radical Scavenging Potency. Neurochemical Research, 2011, 36, 177-186.	3.3	37
42	Mitochondrial functional alterations in relation to pathophysiology of Huntingtonâ€™s disease. Journal of Bioenergetics and Biomembranes, 2010, 42, 217-226.	2.3	29
43	Salicylic acid protects against chronic l-DOPA-induced 6-OHDA generation in experimental model of parkinsonism. Brain Research, 2010, 1344, 192-199.	2.2	20
44	Synthesis of Fluorinated 2,3-Disubstituted Benzofurans Potential Î²-Amyloid Aggregation Inhibitors. Heterocycles, 2010, 80, 663.	0.7	1
45	l-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation. Neurochemistry International, 2010, 56, 357-362.	3.8	26
46	2-Phenylethylamine, a constituent of chocolate and wine, causes mitochondrial complex-I inhibition, generation of hydroxyl radicals and depletion of striatal biogenic amines leading to psycho-motor dysfunctions in Balb/c mice. Neurochemistry International, 2010, 57, 637-646.	3.8	28
47	Earlyâ€life treatment of antiserotonin antibodies alters sensitivity to serotonin receptors, nociceptive stimulus and serotonin metabolism in adult rats. International Journal of Developmental Neuroscience, 2010, 28, 317-324.	1.6	10
48	Melatonin inhibits 6â€hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. Journal of Pineal Research, 2009, 47, 293-300.	7.4	62
49	Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. Neurochemistry International, 2009, 55, 431-437.	3.8	24
50	Reduced NADH coenzyme Q dehydrogenase activity in platelets of Parkinson's disease, but not Parkinson plus patients, from an Indian population. Journal of the Neurological Sciences, 2009, 279, 39-42.	0.6	26
51	Long term L-DOPA treatment causes production of 6-OHDA in the mouse striatum: Involvement of hydroxyl radical. Annals of Neurosciences, 2009, 16, 160-165.	1.7	11
52	Mitochondrial NAD⁺â€linked State 3 respiration and complexâ€I activity are compromised in the cerebral cortex of 3â€nitropropionic acidâ€induced rat model of Huntingtonâ€™s disease. Journal of Neurochemistry, 2008, 104, 420-434.	3.9	73
53	Evidence for Hydroxyl Radical Scavenging Action of Nitric Oxide Donors in the Protection Against 1-Methyl-4-phenylpyridinium-induced Neurotoxicity in Rats. Neurochemical Research, 2008, 33, 985-995.	3.3	10
54	Taurine fails to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion in mice. Amino Acids, 2008, 35, 457-461.	2.7	9

#	Article	IF	Citations
55	In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. Neurochemistry International, 2008, 52, 990-1001.	3.8	43
56	Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism. Behavioural Brain Research, 2007, 184, 11-18.	2.2	37
57	Atropine, a muscarinic cholinergic receptor antagonist increases serotonin, but not dopamine levels in discrete brain regions of mice. Neuroscience Letters, 2007, 423, 100-103.	2.1	9
58	Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. Journal of Pineal Research, 2007, 42, 247-253.	7.4	114
59	Apoptotic Mode of Cell Death in Substantia Nigra Following Intranigral Infusion of the Parkinsonian Neurotoxin, MPP+ in Sprague-Dawley Rats: Cellular, Molecular and Ultrastructural Evidences. Neurochemical Research, 2007, 32, 1238-1247.	3.3	13
60	Long-Term L-DOPA Treatment Causes Indiscriminate Increase in Dopamine Levels at the Cost of Serotonin Synthesis in Discrete Brain Regions of Rats. Cellular and Molecular Neurobiology, 2007, 27, 985-996.	3.3	60
61	Intrastriatal infusion of the Parkinsonian neurotoxin, MPP+, induces damage of striatal cell nuclei in Sprague–Dawley rats. Journal of Chemical Neuroanatomy, 2006, 32, 90-100.	2.1	11
62	l-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochemistry International, 2006, 49, 28-40.	3.8	78
63	Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague–Dawley rats. Brain Research, 2006, 1075, 81-92.	2.2	22
64	Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice. Neuropeptides, 2006, 40, 291-298.	2.2	6
65	Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display differential sensitivity to amphetamine and apomorphine. Pharmacology Biochemistry and Behavior, 2006, 84, 321-329.	2.9	49
66	Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Research, 2005, 1049, 147-155.	2.2	111
67	Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Research, 2005, 1051, 25-34.	2.2	71
68	A synthetic human proline-rich-polypeptide enhances hydroxyl radical generation and fails to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced toxicity in mice. Neuroscience Letters, 2005, 375, 187-191.	2.1	8
69	Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: A comparative study in two mouse strains. Behavioural Brain Research, 2005, 163, 159-167.	2.2	88
70	Evidence for the involvement of central serotonergic mechanisms in cholinergic tremor induced by tacrine in Balb/c mice. Behavioural Brain Research, 2005, 163, 227-236.	2.2	11
71	Aspirin Curtails the Acetaminophen-Induced Rise in Brain Norepinephrine Levels. Metabolic Brain Disease, 2004, 19, 71-77.	2.9	27
72	Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. Journal of Pineal Research, 2004, 36, 25-32.	7.4	106

#	Article	IF	Citations
73	Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochemistry International, 2004, 44, 355-360.	3.8	76
74	Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Research, 2003, 966, 245-252.	2.2	107
75	D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity. Synapse, 2003, 50, 7-13.	1.2	44
76	Calcium channel agonist, (Â±)-Bay K8644, causes a transient increase in striatal monoamine oxidase activity in Balb/c mice. Neuroscience Letters, 2003, 342, 73-76.	2.1	13
77	Calcium channel agonist, (Â±)-Bay K8644, causes an immediate increase in the striatal 1-methyl-4-phenylpyridinium level following systemic administration of the dopaminergic neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, in Balb/c mice. Neuroscience Letters, 2003, 346, 69-72.	2.1	8
78	Serotonin synthesis inhibition in olivo-cerebellar system attenuates harmaline-induced tremor in Swiss albino mice. Behavioural Brain Research, 2003, 145, 31-36.	2.2	33
79	The Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on membrane currents and intrasynaptosomal calcium. Neuroscience Research Communications, 2002, 30, 35-42.	0.2	6
80	Nitric Oxide. Annals of the New York Academy of Sciences, 2002, 962, 389-401.	3.8	83
81	Ayurveda in Parkinsonâ€™s disease. Journal of the Neurological Sciences, 2001, 184, 91-92.	0.6	1
82	Effects of p-chlorophenylalanine on striatal acetylcholinesterase activity and on biogenic amine levels in nuclei raphe and caudate-putamen during physostigmine-induced tremor in rats. Neuroscience Letters, 2001, 299, 105-108.	2.1	13
83	Hypothyroidism in the developing rat brain is associated with marked oxidative stress and aberrant intraneuronal accumulation of neurofilaments. Neuroscience Research, 2001, 40, 273-279.	1.9	58
84	Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Research, 2000, 864, 281-290.	2.2	113
85	Region-specific attenuation of a trypsin-like protease in substantia nigra following dopaminergic neurotoxicity by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Research, 2000, 882, 191-195.	2.2	9
86	In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Research, 2000, 852, 221-224.	2.2	52
87	Effects of serotoninergic drugs on tremor induced by physostigmine in rats. Behavioural Brain Research, 2000, 109, 187-193.	2.2	19
88	Association of l-DOPA with recovery following Ayurveda medication in Parkinsonâ€™s disease. Journal of the Neurological Sciences, 2000, 176, 124-127.	0.6	122
89	Neurochemical Mechanisms Underlying Neuroprotective Actions of Bromocriptine, Salicylate, d- and L-Deprenyl in Neurodegeneration caused by MPTP. , 2000, , 289-293.		8
90	Apparent Role of Hydroxyl Radicals in Oxidative Brain Injury Induced by Sodium Nitroprusside. Free Radical Biology and Medicine, 1998, 24, 1065-1073.	2.9	95

#	Article	IF	Citations
91	Manganese: A transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of Parkinsonism. Neuroscience, 1998, 85, 1101-1111.	2.3	103
92	Behavioral and neurochemical alterations following intracerebroventricular administration of anti-serotonin antibodies in adult Balb/c mice. Journal of Chemical Neuroanatomy, 1998, 14, 141-149.	2.1	4
93	Neuroprotection by nitric oxide against hydroxyl radical-induced nigral neurotoxicity. Journal of Chemical Neuroanatomy, 1998, 14, 195-205.	2.1	63
94	Neuroprotection by bromocriptine against 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridineâ€induced neurotoxicity in mice¹. FASEB Journal, 1998, 12, 905-912.	0.5	219
95	S-nitrosothiols and nitric oxide, but not sodium nitroprusside, protect nigrostriatal dopamine neurons against iron-induced oxidative stress in vivo. , 1996, 23, 58-60.		85
96	Neonatal treatment with 5-HT antiserum alters 5-HT metabolism and function in adult rats. NeuroReport, 1995, 7, 238-240.	1.2	9
97	Neonatal treatment with 5-HT antiserum alters 5-HT metabolism and function in adult rats. NeuroReport, 1995, 7, 238-240.	1.2	1
98	In Vivo Generation of Hydroxyl Radicals and MPTPâ€induced Dopaminergic Toxicity in the Basal Ganglia. Annals of the New York Academy of Sciences, 1994, 738, 25-36.	3.8	104
99	Antioxidant Mechanism and Protection of Nigral Neurons Against MPP⁺ Toxicity by Deprenyl (Selegiline). Annals of the New York Academy of Sciences, 1994, 738, 214-221.	3.8	55
100	Ferrousâ€Citrate Complex and Nigral Degeneration: Evidence for Freeâ€radical Formation and Lipid Peroxidation^a. Annals of the New York Academy of Sciences, 1994, 738, 392-399.	3.8	104
101	Resistance of Golden Hamster to lâ€Methylâ€4â€Phenylâ€1,2,3,6 Tetrahydropyridine: Relationship with Low Levels of Regional Monoamine Oxidase B. Journal of Neurochemistry, 1994, 62, 1906-1912.	3.9	40
102	Dissociation of serotoninergic and dopaminergic components in acute effects of 1-methy 1-4-pheny 1-1,2,3,6-tetrahydropyridine in mice. Brain Research Bulletin, 1992, 28, 355-364.	3.0	41
103	Supersensitivity of spinal dopaminergic receptors in rat after chronic haloperidol. Brain Research Bulletin, 1992, 28, 133-135.	3.0	5
104	Tremorogenesis by physostigmine is unrelated to acetylcholinesterase inhibition: Evidence for serotoninergic involvement. Neuroscience Letters, 1990, 120, 91-93.	2.1	15
105	5-Hydroxytryptamine in the phrenic nerve diaphragm: Evidence for its existence and release. Neuroscience Letters, 1989, 97, 345-349.	2.1	5
106	Tremorogenesis by LON-954 [N-carbamoyl-2-(2,6-dichlorophenyl) acetamidine hydrochloride]: Evidence for the involvement of 5-hydroxytryptamine. Brain Research Bulletin, 1989, 22, 191-195.	3.0	8
107	Fluctuations of acetylcholinesterase in the mouse spinal cord and in vivo sodium effect during the development of morphine tolerance, dependence, and withdrawal. Neurochemical Research, 1986, 11, 505-520.	3.3	3
108	Acetylcholinesterase changes in the central nervous system of mice during the development of morphine tolerance addiction and withdrawal. Brain Research Bulletin, 1983, 10, 589-596.	3.0	12

#	Article	IF	Citations
109	Distribution of Carboxylic Esterases in the Telencephalon and Diencephalon of a Microchiropteran Bat (<i>Taphozous melanopogo</i><i>n</i> Temminck). Cells Tissues Organs, 1983, 116, 312-321.	2.3	0
110	Glycosidases and Lipid Metabolism in the Central Nervous System of the Hedgehog (<i>Paraechinus micropus</i>). Cells Tissues Organs, 1982, 114, 339-346.	2.3	1